CVM Overview

Adaptimmune Therapeutics Surge: Adaptimmune Therapeutics plc (ADAP) saw a dramatic after-hours increase of 30% following a nearly 98% gain during regular trading, driven by renewed investor interest despite no specific news. The company reported a net loss of $30.3 million for Q2 2025 but has made strategic moves, including selling cell therapies for $55 million.

Butterfly Network Recognition: Butterfly Network Inc. (BFLY) rose 10.58% in after-hours trading after being named one of TIME's Top HealthTech Companies for 2025, alongside a recent appointment of a new CTO. The company’s technology has been validated by a JAMA study showing significant reductions in hospital stays and costs.

Aquestive Therapeutics Positive Outlook: Aquestive Therapeutics Inc. (AQST) continued its upward trend with a 7.69% increase in after-hours trading, bolstered by FDA confirmation that no advisory committee meeting is needed for its NDA for Anaphylm, streamlining the approval process. The company also secured $75 million in strategic funding.

Insider Confidence at ALX Oncology: ALX Oncology Holdings Inc. (ALXO) gained 9.17% in after-hours trading, attributed to insider buying by CEO Jason Lettmann, signaling confidence in the company. ALXO's lead candidate, Evorpacept, is currently in multiple clinical trials, maintaining investor interest despite no new data releases.

Market Overview: U.S. stock futures showed mixed results following gains from the previous day, with Nvidia Corp. experiencing a decline despite reporting better-than-expected second-quarter results.

Nvidia's Performance: Nvidia's stock fell due to lack of guidance on H20 shipments to China and weaker data center revenue, although analysts remain optimistic about its leadership in AI infrastructure.

Economic Indicators: The 10-year Treasury bond yield was at 4.23%, with markets anticipating an 87.3% chance of interest rate cuts by the Federal Reserve in September; mortgage applications also saw a slight decline.

Stock Movements: Notable stock movements included MongoDB Inc. rising 38% after strong earnings, while Kohl’s Corp. gained 24%. Conversely, CEL-SCI Corp. dropped 30.83% after announcing a public offering.

Snowflake Inc. Financial Results: Snowflake's shares surged 14.2% in pre-market trading after reporting second-quarter revenue of $1.14 billion and adjusted earnings of 35 cents per share, both exceeding analyst expectations.

Other Gainers in Pre-Market Trading: Several stocks saw significant gains, including Erayak Power Solution Group (up 52.5%), Top KingWin Ltd (up 50.5%), and Telomir Pharmaceuticals (up 43.9%).

Notable Losers in Pre-Market Trading: CEL-SCI Corporation experienced a sharp decline of 29.8% following a public offering announcement, while The Cooper Companies and Cognition Therapeutics also reported losses of 14.5% and 14.1%, respectively.

NVIDIA's Performance: NVIDIA shares fell 2% despite reporting better-than-expected earnings and projecting third-quarter revenue within the consensus estimate range.

Stock Price Decline: CEL-SCI Corporation's shares fell 38.19% to $8.06 after announcing a $10 million public offering priced below market levels.

Offering Details: The company priced 1,111,200 common shares at $9.00 each, a 30.9% discount from the previous closing price of $13.04, with the offering expected to close on August 29.

Use of Proceeds: Funds from the offering will be used for the development of Multikine, a cancer immunotherapy candidate, as well as general corporate purposes and working capital.

Market Performance: Over the past year, CEL-SCI's stock has fluctuated between $1.98 and $39.30, with a current market capitalization of $89.74 million.